Cypermethrin Poisoning

Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Clinical judgment is paramount, and treatment decisions must be individualized based on patient presentation, available resources, and local guidelines.

Overview

• Definition: Cypermethrin is a synthetic pyrethroid insecticide widely used in agriculture, public health (e.g., mosquito control), and domestic settings. Poisoning occurs due to exposure, typically through dermal, inhalation, or oral routes, leading to neurological and other systemic effects. It is classified as a Type II pyrethroid due to the presence of an alpha-cyano group, which differentiates its toxicodynamic effects from Type I pyrethroids.
• Epidemiology: Cypermethrin poisoning is common in agricultural regions, particularly in developing countries, often due to occupational exposure (e.g., during spraying without adequate protective equipment), accidental ingestion (especially in children), or intentional self-harm. Domestic exposures can occur from household insecticide use. While generally considered to have low mammalian toxicity compared to organophosphates, high-dose exposures can lead to significant morbidity and, rarely, mortality.
• Classification:
  • Chemical Class: Synthetic Pyrethroid, Type II.
  • Exposure Routes: Dermal, Inhalation, Ocular, Oral.
  • Severity: Mild, Moderate, Severe, based on clinical manifestations.

Pathophysiology

• Mechanism: Cypermethrin, like other pyrethroids, acts primarily on voltage-gated sodium channels in neurons. It prolongs the opening of these channels, leading to repetitive firing of neurons. This results in hyperexcitability of the central and peripheral nervous systems.
  • Type II Pyrethroid Specifics: The alpha-cyano group in Type II pyrethroids like cypermethrin leads to a longer opening time of sodium channels compared to Type I pyrethroids, contributing to more pronounced neurological effects, including choreoathetosis and seizures, often referred to as the "T-syndrome" (tremor, salivation, seizures, choreoathetosis).
  • Solvent Effects: Most commercial formulations of cypermethrin are dissolved in hydrocarbon solvents (e.g., xylene, kerosene). The solvents themselves can cause significant toxicity, especially if ingested, leading to aspiration pneumonitis, CNS depression, and cardiac arrhythmias. The clinical picture is often a combination of pyrethroid and solvent toxicity.
• Risk Factors:
  • Occupational exposure (farmers, pest control operators) without proper personal protective equipment (PPE).
  • Accidental ingestion (especially in children who mistake the product for beverages).
  • Intentional self-harm or suicide attempts.
  • Improper storage of pesticides in unlabeled containers.
  • Application in poorly ventilated areas.
  • Presence of skin lesions or abrasions facilitating dermal absorption.
• Protective Factors:
  • Strict adherence to PPE guidelines (gloves, masks, protective clothing, eye protection) during handling and application.
  • Safe storage of pesticides in original, labeled containers, secured away from children and unauthorized access.
  • Public education on pesticide safety.
  • Proper ventilation during indoor application.
  • Avoiding eating, drinking, or smoking during pesticide application.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Dermal Exposure: Paresthesia (itching, tingling, burning, numbness, especially perioral), erythema, localized rash. This is the most common symptom.
  • Inhalation Exposure: Cough, shortness of breath, throat irritation, nasal discharge.
  • Oral Ingestion: Nausea, vomiting, abdominal pain, diarrhea.
  • Systemic (severe exposure): Dizziness, headache, fatigue, muscle weakness, fasciculations, tremors, hyperreflexia, ataxia, seizures, altered mental status (confusion, lethargy, coma), respiratory distress.
• Early Signs:
  • Dermal: Localized paresthesia (often described as "pins and needles" or "stinging"), burning sensation on exposed skin.
  • Oral: Nausea, vomiting, abdominal discomfort.
  • Ocular: Eye irritation, tearing, conjunctivitis.
• Advanced Signs:
  • Neurological: Severe tremors, myoclonic jerks, generalized tonic-clonic seizures, status epilepticus, severe ataxia, profound altered mental status (stupor, coma).
  • Respiratory: Severe dyspnea, bronchospasm, cyanosis, respiratory failure (often due to aspiration pneumonitis from hydrocarbon solvent ingestion or severe CNS depression).
  • Cardiovascular: Bradycardia or tachycardia, hypotension (less common, usually in severe cases with shock).
  • Gastrointestinal: Severe abdominal pain, protracted vomiting, gastrointestinal bleeding (rare).
• Atypical Presentations:
  • Delayed onset of severe neurological symptoms (e.g., seizures appearing hours after exposure).
  • Predominant solvent toxicity masking pyrethroid effects (e.g., early CNS depression and aspiration pneumonitis).
  • Allergic reactions (urticaria, angioedema) in susceptible individuals.

Physical Examination

• Inspection:
  • Skin: Erythema, rash, signs of chemical burns, sweating. Paresthesia can be elicited by light touch or blowing air on the affected area.
  • Eyes: Conjunctival injection, corneal abrasions (if direct splash).
  • Neurological: Tremors (fine or coarse), fasciculations (especially around the mouth or eyes), ataxia, nystagmus, altered level of consciousness (from somnolence to coma).
  • Respiratory: Increased work of breathing, accessory muscle use, cyanosis.
  • Gastrointestinal: Abdominal distension, tenderness.
  • Oral: Perioral numbness/tingling, drooling.
• Palpation:
  • Skin: Tenderness or warmth in areas of dermal exposure.
  • Abdomen: Tenderness, guarding.
  • Pulse: Bradycardia or tachycardia.
• Special Tests:
  • Neurological Exam: Assessment of cranial nerves, motor strength, reflexes (hyperreflexia may be present), coordination (Romberg, finger-to-nose).
  • Respiratory Auscultation: Crackles, wheezes, or diminished breath sounds suggestive of aspiration pneumonitis or bronchospasm.

Diagnostic Approach

History Taking

• Key Questions:
  • Substance Identification: What was the exact product name? (Crucial for identifying active ingredients and solvents). Request product container or label if available.
  • Route of Exposure: Oral (ingestion), dermal (skin contact), inhalation, ocular splash.
  • Amount of Exposure: Estimate the quantity ingested, spilled, or duration of inhalation.
  • Time of Exposure: When did the exposure occur? This helps predict symptom onset and guide decontamination.
  • Circumstances of Exposure: Accidental, occupational, intentional? (Important for risk assessment and psychosocial support).
  • Symptoms Onset and Progression: What symptoms appeared first? How have they progressed?
  • Co-ingestants: Was anything else ingested (e.g., alcohol, other drugs/medications)?
  • Past Medical History: Pre-existing respiratory, neurological, or cardiac conditions.
  • First Aid: What interventions were attempted prior to arrival (e.g., vomiting induced, milk given, bathing)?
• Red Flags:
  • Any ingestion, especially of large volumes or concentrated formulations.
  • Development of neurological symptoms: tremors, muscle fasciculations, altered mental status, seizures.
  • Respiratory distress, cough, or signs of aspiration.
  • Hemodynamic instability.
  • Suicidal intent.
  • Exposure in children.

Laboratory Tests

• First-Line: Primarily supportive, as specific cypermethrin levels are not readily available or clinically useful for acute management.
  • Complete Blood Count (CBC): To assess for leukocytosis (non-specific, can indicate stress or infection).
  • Electrolytes (Na, K, Cl, Bicarbonate): To assess for electrolyte imbalances, especially if vomiting or dehydration.
  • Renal Function Tests (BUN, Creatinine): To assess kidney function.
  • Liver Function Tests (ALT, AST, Bilirubin): To assess hepatic involvement, though liver injury is rare with cypermethrin alone.
  • Arterial Blood Gas (ABG) or Venous Blood Gas (VBG): If respiratory distress or altered mental status is present, to assess oxygenation, ventilation, and acid-base status.
  • Blood Glucose: To rule out hypoglycemia as a cause of altered mental status or seizures.
  • Urinalysis: To assess for renal damage.
  • Serum Acetone (if solvent suspected): Some hydrocarbon solvents may be metabolized to ketones.
• Confirmatory:
  • Confirmation of cypermethrin exposure typically relies on history and characteristic clinical syndrome.
  • Analytical testing for cypermethrin or its metabolites in blood or urine is possible in specialized toxicology laboratories but rarely contributes to acute clinical management decisions due to delayed results. Its role is primarily forensic or for research.
• Monitoring:
  • Serial ABG/VBG if respiratory compromise.
  • Repeat electrolytes, renal, and liver function tests if initial values are abnormal or if the patient's condition deteriorates.
  • Continuous cardiac monitoring (ECG) if signs of cardiovascular instability are present.

Imaging

• Recommended:
  • Chest X-ray (CXR): Indicated for any patient with cough, dyspnea, hypoxemia, or signs of aspiration after ingestion of cypermethrin (especially if hydrocarbon solvent-based) to evaluate for aspiration pneumonitis or acute respiratory distress syndrome (ARDS).
• Advanced:
  • Head CT Scan: Consider in patients with severe, refractory seizures, focal neurological deficits, or profound altered mental status where an alternative neurological cause (e.g., stroke, hemorrhage) is suspected or cannot be ruled out.
  • Abdominal X-ray: Rarely helpful, but can sometimes show radiopaque foreign bodies if other ingestions are suspected.

Management

Acute Management

• Immediate: Prioritize airway, breathing, and circulation (ABCs).
  • Airway: Assess airway patency. Be prepared for intubation if respiratory compromise (e.g., severe aspiration, CNS depression, seizures) or inability to protect the airway.
  • Breathing: Provide supplemental oxygen to maintain SpO2 > 94%. Assist ventilation if needed. Assess for bronchospasm (wheezing) or aspiration pneumonitis (crackles, decreased breath sounds).
  • Circulation: Establish IV access. Monitor heart rate and blood pressure. Treat hypotension with IV fluids (isotonic crystalloids) if hypovolemic, or vasopressors if refractory to fluids.
• Stabilization:
  • Decontamination:
    • Dermal Exposure: Remove contaminated clothing. Wash exposed skin thoroughly with soap and copious amounts of water for at least 15-20 minutes. Pay attention to skin folds, hair, and under nails. Healthcare providers should wear appropriate PPE (gloves, gowns).
    • Ocular Exposure: Irrigate eyes with copious amounts of normal saline or water for at least 15-20 minutes. Consider fluorescein stain and slit lamp examination to assess for corneal injury.
    • Oral Ingestion:
      • Activated Charcoal: Administer activated charcoal (AC) 1 g/kg (max 50-100 g for adults, 25-50 g for children) orally or via NG tube within 1-2 hours of ingestion, provided the patient is conscious and has an intact gag reflex to protect the airway.
      • Contraindications for AC: Patients with unprotected airway, risk of aspiration (e.g., depressed mental status, seizures), or ingestion of substances where AC is ineffective (e.g., pure hydrocarbons without significant co-ingestants, heavy metals, strong acids/bases). Given the common presence of hydrocarbon solvents in cypermethrin formulations, careful assessment of aspiration risk is crucial. Gastric lavage is generally NOT recommended due to high aspiration risk and unproven benefit.
      • Emesis: Do NOT induce vomiting (ipecac syrup is contraindicated) due to high risk of aspiration, especially with hydrocarbon solvents.
  • Seizure Management:
    • First-line: Benzodiazepines are the mainstay.
      • Lorazepam: 0.1 mg/kg IV (max 4 mg) every 5-10 minutes until seizures stop.
      • Diazepam: 0.1-0.2 mg/kg IV (max 10 mg) every 5-10 minutes until seizures stop.
      • Midazolam: 0.2 mg/kg IM/IN or 0.1 mg/kg IV.
    • Second-line/Refractory: If seizures persist despite adequate benzodiazepine doses, consider phenobarbital (15-20 mg/kg IV loading dose) or propofol/fosphenytoin in consultation with toxicology/critical care.
  • Respiratory Support:
    • Bronchospasm: Administer inhaled beta-2 agonists (e.g., albuterol).
    • Aspiration Pneumonitis: Supportive care, oxygen, ventilation as needed. Antibiotics are generally not indicated unless there's evidence of bacterial superinfection.
• Emergency:
  • Manage life-threatening complications (e.g., status epilepticus, severe respiratory failure, cardiovascular collapse) aggressively following advanced resuscitation protocols.
  • Consult a regional Poison Control Center or Medical Toxicologist immediately for expert guidance.

Chronic Management

• Pharmacological:
  • There is no specific antidote for cypermethrin poisoning. Management is entirely supportive.
  • Medications are used to manage symptoms and complications (e.g., antiemetics for nausea/vomiting, analgesics for pain, antipyretics for fever).
  • Antibiotics if bacterial pneumonia secondary to aspiration is confirmed.
• Non-pharmacological:
  • Supportive Care: Good nursing care, fluid and electrolyte management, nutritional support.
  • Respiratory Care: Chest physiotherapy, suctioning, ventilator support if needed.
  • Skin Care: For extensive dermal exposure, prevent secondary skin infections.
  • Psychosocial Support: For intentional self-harm cases, psychiatric evaluation and follow-up are essential after medical stabilization.
• Monitoring:
  • Continuous vital signs monitoring until stable.
  • Neurological status assessment (GCS, pupil response, seizure activity) frequently.
  • Respiratory status (SpO2, respiratory rate, breath sounds).
  • Fluid input/output.
  • Repeat laboratory tests (electrolytes, renal, liver function, ABG) as clinically indicated based on patient condition and initial abnormalities.
  • Serial chest X-rays if aspiration pneumonitis or other pulmonary complications are present.

Treatment Algorithms

• First-Line:
  1. ABCs and Decontamination: Secure airway, provide oxygen/ventilation if needed. Initiate aggressive dermal/ocular decontamination or activated charcoal for oral ingestion (if safe).
  2. Seizure Control: IV benzodiazepines (Lorazepam 0.1 mg/kg or Diazepam 0.1-0.2 mg/kg).
  3. Supportive Care: IV fluids for hypotension, antiemetics for vomiting, close monitoring.
• Second-Line:
  1. Refractory Seizures: Consider second-line anticonvulsants (e.g., phenobarbital, fosphenytoin, propofol infusion) and emergent head CT if not already performed.
  2. Respiratory Failure: Mechanical ventilation, treatment of aspiration pneumonitis.
  3. Hemodynamic Instability: Vasopressors (e.g., norepinephrine) if hypotension refractory to fluids.
• Refractory Cases:
  • Status Epilepticus: May require continuous infusions of sedatives/anticonvulsants (e.g., midazolam, propofol) and possible induced coma in the ICU setting.
  • Severe ARDS/Pneumonitis: May require advanced ventilatory strategies (e.g., prone positioning, high-frequency oscillatory ventilation, ECMO) in specialized centers.
  • Multisystem Organ Dysfunction: Continue aggressive supportive care, managing each organ system failure symptomatically.
  • Consultation with medical toxicology and critical care specialists is paramount for refractory cases.

Complications

• Common:
  • Aspiration pneumonitis (from hydrocarbon solvent ingestion, major concern).
  • Persistent paresthesia.
  • Dehydration due to vomiting.
  • Skin irritation, contact dermatitis.
• Serious:
  • Generalized tonic-clonic seizures, status epilepticus.
  • Respiratory failure requiring mechanical ventilation (due to CNS depression, aspiration, or severe bronchospasm).
  • Acute respiratory distress syndrome (ARDS).
  • Hypoxic-ischemic encephalopathy secondary to prolonged seizures or respiratory arrest.
  • Acute kidney injury (rare, but possible with severe rhabdomyolysis from prolonged seizures).
  • Death (rare, usually associated with massive ingestion, aspiration, or delayed treatment of severe complications).
• Long-term:
  • Chronic neurological deficits (e.g., cognitive impairment, motor dysfunction) after severe anoxic brain injury from respiratory arrest or prolonged status epilepticus.
  • Persistent pulmonary symptoms (e.g., chronic cough, reduced lung function) after severe aspiration pneumonitis.
  • Psychiatric sequelae following intentional self-harm.

Prognosis

• Factors:
  • Dose and Concentration: Higher doses and more concentrated formulations are associated with worse outcomes.
  • Route of Exposure: Oral ingestion (especially with hydrocarbon solvents) carries a higher risk of systemic toxicity and aspiration than dermal or inhalation exposure.
  • Time to Decontamination and Treatment: Prompt and effective intervention improves prognosis.
  • Presence of Complications: Development of seizures, aspiration pneumonitis, respiratory failure, or hemodynamic instability significantly worsens prognosis.
  • Underlying Health Status: Patients with pre-existing respiratory, neurological, or cardiac conditions may have worse outcomes.
• Survival: The overall prognosis for isolated pyrethroid poisoning is generally good with prompt and aggressive supportive care, as they have relatively low mammalian toxicity compared to other pesticides. Mortality is rare but primarily associated with massive ingestions, severe aspiration pneumonitis, or refractory status epilepticus.
• Quality of Life: Most patients with mild to moderate exposure recover without long-term sequelae. Those who experience severe complications (e.g., prolonged anoxia, extensive aspiration damage) may have persistent neurological or pulmonary deficits affecting their quality of life.

Prevention

• Primary: Preventing initial occurrence of poisoning.
  • Education: Public and occupational education on safe handling, storage, and disposal of pesticides.
  • Personal Protective Equipment (PPE): Mandatory use of appropriate PPE (gloves, long-sleeved clothing, respirators, eye protection) for individuals handling cypermethrin.
  • Safe Storage: Store pesticides in their original, labeled containers, in locked cabinets or areas inaccessible to children and unauthorized persons.
  • Child-resistant Packaging: Promote and enforce child-resistant packaging for household pesticide products.
  • Avoidance of Decanting: Never transfer pesticides into unlabeled bottles, especially food or beverage containers.
  • Ventilation: Ensure adequate ventilation during pesticide application in enclosed spaces.
  • Agricultural Practices: Promote integrated pest management (IPM) to reduce reliance on chemical pesticides.
• Secondary: Early detection and intervention to minimize the impact of poisoning.
  • Rapid identification of exposure and prompt presentation to medical facilities.
  • Immediate first aid measures (e.g., thorough skin washing, eye irrigation).
  • Emergency medical services (EMS) rapid response and transport.
• Tertiary: Preventing complications and improving outcomes in poisoned individuals.
  • Aggressive supportive care and management of complications as outlined in the "Management" section.
  • Rehabilitation for those with long-term deficits.
  • Psychiatric follow-up for intentional self-harm cases.

Special Populations

• Pediatric:
  • Higher Vulnerability: Children are more susceptible to the effects of pesticides due to their smaller body mass, higher metabolic rate, immature organ systems, and higher body surface area to volume ratio (for dermal exposures).
  • Accidental Ingestion: Accidental ingestion is a major concern, often due to improper storage (e.g., pesticides in soda bottles).
  • Dosing: All drug dosages must be weight-based.
  • Decontamination: Activated charcoal dosing is 1 g/kg (max 25-50g). Careful assessment of airway protection is critical before administration.
  • Fluid Management: Careful fluid management due to higher risk of fluid overload or dehydration.
• Geriatric:
  • Comorbidities: Elderly patients often have pre-existing medical conditions (renal, hepatic, cardiac, neurological) that can complicate poisoning and treatment.
  • Polypharmacy: Increased risk of drug-drug interactions with prescribed medications.
  • Reduced Physiological Reserve: May tolerate toxic effects and therapeutic interventions less well.
  • Cognitive Impairment: May make history taking challenging and increase risk of accidental exposure.
• Pregnancy:
  • Fetal Risk: Potential for transplacental passage of cypermethrin, though human data on fetal effects are limited. Hydrocarbon solvents can also be fetotoxic.
  • Management: Maternal stabilization is the priority. Decontamination and supportive care are similar to non-pregnant adults. Avoid medications that are contraindicated in pregnancy where possible, but prioritize maternal life-saving interventions. Consult with an obstetrician and medical toxicologist.
• Comorbidities:
  • Respiratory Disease (Asthma, COPD): Increased risk of severe bronchospasm or aspiration pneumonitis complications. Close monitoring and aggressive respiratory support.
  • Neurological Disorders (Epilepsy, Stroke History): Increased susceptibility to seizures or worsening of neurological deficits. May require higher doses or earlier administration of anticonvulsants.
  • Cardiac Disease: Close cardiac monitoring. Avoid drugs that may exacerbate arrhythmias.
  • Renal/Hepatic Impairment: May affect drug metabolism and elimination; dose adjustments for renally/hepatically cleared medications may be necessary.

Clinical Pearls

• Diagnostic:
  • "Smell the Bottle": If possible and safe, smelling the container can give a clue to hydrocarbon solvent presence.
  • Perioral Paresthesia: A classic early symptom of pyrethroid exposure, particularly after dermal contact or ingestion. Ask specifically about "tingling," "burning," or "numbness" around the mouth.
  • Hydrocarbon Solvent Toxicity: Always consider concomitant solvent toxicity in cypermethrin poisoning, especially with ingestions. Aspiration pneumonitis is a major concern, often presenting with cough, dyspnea, and CXR changes.
  • Lab Tests Limitations: Remember that specific cypermethrin levels are generally not available or useful in acute management; diagnosis is primarily clinical.
• Treatment:
  • Decontamination First: Rapid and thorough decontamination is critical for minimizing absorption, especially for dermal exposures.
  • Airway Protection is Paramount: Prioritize airway management, especially when considering activated charcoal for ingestions. If the patient has a depressed mental status or impaired gag reflex, intubate before giving charcoal.
  • Benzodiazepines for Seizures: They are the cornerstone of treatment for pyrethroid-induced seizures and generally very effective. Do not hesitate to give adequate doses.
  • No Specific Antidote: Emphasize that management is supportive.
• Pitfalls:
  • Delay in Decontamination: Failure to promptly remove contaminated clothing and wash skin thoroughly.
  • Inducing Vomiting: This is a major error due to the high risk of aspiration, especially with hydrocarbon solvent formulations.
  • Overlooking Solvent Toxicity: Focusing solely on the pyrethroid and missing the significant contribution of the hydrocarbon solvent to the clinical picture (e.g., aspiration pneumonitis, CNS depression).
  • Underdosing Benzodiazepines: Not using sufficient doses of benzodiazepines for seizure control due to fear of sedation.
  • Discharging Too Early: Patients, especially children, who have ingested hydrocarbon solvent-based products should be observed for at least 6-8 hours for signs of aspiration pneumonitis, even if initially asymptomatic. CXR may become abnormal later.

Recent Updates

• Guidelines: Current guidelines for pyrethroid poisoning largely remain consistent with principles of aggressive decontamination and supportive care. There are no major recent paradigm shifts. Management strategies are often derived from general toxicology principles and experience with other pesticide poisonings.
• Evidence: Recent research often focuses on specific neurotoxic mechanisms, long-term effects of chronic low-level exposure, and development of safer alternatives. Acute management principles have not seen major changes, though continued emphasis on early recognition and supportive care is reinforced.
• Controversies:
  • Optimal Duration of Observation: While 6-8 hours is a common observation period for hydrocarbon aspiration risk, some advocate for longer periods based on the specific solvent.
  • Role of Lipid Emulsion Therapy: Intravenous lipid emulsion therapy has been explored in various lipophilic toxin poisonings. While primarily for local anesthetic systemic toxicity, there is limited case report data for other highly lipophilic toxins, including some pesticides. Its role in pyrethroid poisoning is investigational and not routinely recommended, but may be considered in very severe, refractory cases in consultation with toxicology.

Key References

• Guidelines:
  • World Health Organization (WHO) Guidelines on Pesticide Poisoning Management. (General principles applicable).
  • Position papers from the American Academy of Clinical Toxicology (AACT) and European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) on gastrointestinal decontamination.
  • Local Poison Control Center guidelines.
• Studies:
  • Numerous case reports and series describe clinical features and outcomes of pyrethroid poisoning. Specific landmark studies are less common due to the supportive nature of treatment.
  • Toxicology textbooks and reviews provide comprehensive summaries of the mechanism and management.
• Reviews:
  • Roberts, D. M., & Reith, D. (2018). Clinical Toxicology of Pyrethroids. In R. C. Dart (Ed.), Medical Toxicology (3rd ed., pp. 1195-1200). Wolters Kluwer.
  • Bradberry, S. M., Cage, S. A., Proudfoot, A. T., & Vale, J. A. (2005). Poisoning due to pyrethroids. Toxicological Reviews, 24(2), 93-106.
  • Various chapters on pesticide poisoning in general toxicology textbooks (e.g., Goldfrank's Toxicologic Emergencies, Poisoning & Drug Overdose by Olson).

---

This comprehensive clinical reference is provided for informational and educational purposes only and does not constitute medical advice. Clinicians must always apply their professional judgment in patient care.